Propofol

證據等級: L5

預測適應症: 5 個

Propofol: From General Anaesthesia to Migraine Disorder

One-Sentence Summary

Propofol is a short-acting intravenous general anaesthetic and sedative agent, widely used in clinical practice for induction and maintenance of anaesthesia. The TxGNN model predicts it may be effective for Migraine Disorder, with 5 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	General anaesthesia and procedural sedation
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.69%
Evidence Level	L1
NL Market Status	Not registered (no CBG-MEB authorizations found in current dataset)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on published literature, Propofol (2,6-diisopropylphenol) is an intravenous anaesthetic that primarily enhances inhibitory neurotransmission through potentiation of GABA-A receptors in the central nervous system.

Migraine pathophysiology involves two key mechanisms that Propofol is known to modulate: (1) central sensitisation of the trigeminal pain pathway, and (2) cortical spreading depression (CSD) — the electrophysiological event underlying migraine aura and a key trigger for migraine pain. Preclinical data (PMID 22390898) demonstrate that Propofol hemisuccinate suppresses CSD propagation. At sub-anaesthetic doses — substantially lower than those required for full sedation — Propofol can interrupt an acute migraine attack without inducing unconsciousness, suggesting a pharmacologically specific action rather than a non-specific sedative effect.

This mechanistic rationale is reinforced by over two decades of clinical observation in emergency department settings. Multiple randomised trials and a 2025 American Headache Society practice guideline now include Propofol among parenteral options for migraine patients who fail standard first-line treatment (dopamine antagonists, NSAIDs). The consistent signal across paediatric and adult populations, combined with a systematic review and network meta-analysis, elevates this from a mechanistic hypothesis to a clinically plausible repurposing candidate.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01604785	Phase 2/3	Completed	74	Prospective RCT testing low-dose Propofol for abortive therapy of acute paediatric migraine in the ED; the highest-quality direct trial evidence for this indication to date
NCT02485418	NA	Completed	40	Evaluated efficacy and safe dosing limits of low-dose Propofol infusion as an abortive agent in the paediatric migraine population; complements NCT01604785
NCT02492295	NA	Terminated	12	Designed to study low-dose Propofol for severe refractory migraine in adult ED patients; terminated early with insufficient enrolment (n=12), results inconclusive
NCT03789370	NA	Unknown	130	Compared anaesthetic maintenance agents (Propofol vs sevoflurane) on postoperative headache incidence; indirect evidence only, not a therapeutic migraine trial

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35402989	2022	RCT	Archives of Academic Emergency Medicine	Double-blind RCT comparing Propofol + granisetron vs Propofol + metoclopramide for acute migraine symptom management in the ED
29456086	2018	RCT	The Journal of Emergency Medicine	Prospective RCT of sub-anaesthetic Propofol for paediatric ED migraine; assessed efficacy and side-effect profile with favourable results
35573713	2022	RCT	Archives of Academic Emergency Medicine	RCT evaluating sumatriptan + Propofol combination vs sumatriptan alone for acute migraine; assessed whether Propofol provides additive benefit
32705801	2020	RCT (Pilot)	Emergency Medicine Australasia	Pilot RCT comparing IV Propofol at procedural sedation dose vs standard therapy for initial migraine management in the ED
31621134	2020	Systematic Review	Academic Emergency Medicine	Systematic review evaluating safety and efficacy of Propofol for acute migraine treatment in the ED; summarises all available evidence up to 2020
39364614	2024	Systematic Review + Network Analysis	Headache	Network meta-analysis comparing parenteral agents for reducing migraine relapse after severe acute presentations; includes Propofol
41321235	2026	Practice Guideline	Headache	2025 American Headache Society update on parenteral pharmacotherapies for migraine in the ED; provides current evidence-based positioning of Propofol
27454834	2016	Narrative Review	Expert Review of Neurotherapeutics	Comprehensive drug profile of Propofol for super-refractory migraine at sub-anaesthetic doses; covers pharmacology and clinical evidence
32638172	2020	Narrative Review	Current Pain and Headache Reports	Review of IV migraine treatments in children and adolescents in the paediatric ED, including a summary of Propofol evidence
22309235	2012	Narrative Review	Headache	Part of a 3-part series on rescue therapy for acute migraine; covers Propofol among neuroleptics, antihistamines, and other agents in emergency settings

Netherlands Market Information

No CBG-MEB marketing authorizations for Propofol were identified in the current dataset (total licenses: 0, market status: not registered). This likely reflects a data extraction gap rather than true unavailability — Propofol-containing products (e.g., Diprivan®, Fresenius Kabi Propofol) are routinely used in Dutch hospital anaesthesia practice and are expected to hold valid RVG numbers. A direct verification against the CBG-MEB product register is required before drawing any regulatory conclusion.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for safety information.

Important note for off-label use evaluation: No safety data — including warnings, contraindications, or drug–drug interactions — was available in this evidence pack. Given that Propofol is a potent intravenous anaesthetic with narrow therapeutic margins (risk of respiratory depression, apnoea, and haemodynamic compromise even at sub-anaesthetic doses), a full review of the current Dutch SmPC is essential prior to any off-label use consideration, particularly outside a monitored anaesthesia care setting.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple randomised controlled trials, a 2020 systematic review, and a 2025 American Headache Society practice guideline collectively support the use of sub-anaesthetic Propofol for acute, refractory migraine in the emergency department — justifying advancement to a structured feasibility and regulatory review.

To proceed, the following is needed:

Confirm CBG-MEB registration status: Cross-check Propofol products against the official CBG-MEB register and obtain the applicable Dutch SmPC(s)
Safety review: Complete a full contraindication and drug interaction assessment from the SmPC; clarify minimum monitoring requirements (e.g., pulse oximetry, IV access, resuscitation equipment) for sub-anaesthetic use outside the operating theatre
Define target population: Specify the clinical context (adult vs paediatric; second-line ED treatment for refractory migraine) to scope the off-label use appropriately
Guideline alignment: Review the 2025 AHS guideline (PMID 41321235) and any applicable Dutch neurological or emergency medicine guidelines to determine whether Propofol is already recognised or excluded for this indication in the Netherlands
Regulatory pathway: Determine whether an off-label use protocol, hospital formulary amendment, or formal indication extension would be the appropriate regulatory route under the CBG-MEB/EMA framework
Pharmacovigilance plan: Establish a post-use monitoring protocol for respiratory and haemodynamic adverse events in the Dutch clinical setting
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.